![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
Patents Vis-a-Vis Health–The Novartis Issue: An Analysis
The TRIPS Agreement has created unprecedented changes in the Patenting Law and the most affected of this is the Indian Pharmaceutical Industry. The current article is a case study of one of the most famous case in the Pharmaceutical Industry which is set to change the outlook of the Indian Pharmaceutical Industry to the outside world.
Keywords
Pharmaceutical, Patent, Infringememnt.
User
Font Size
Information
- Available at, http://www.imshealth.com/portal/site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=01624605b5367210VgnVCM100000ed152ca2RCRD, visited on 15th Feb. 2015
- Available at, http://www.economist.com/blogs/schumpeter/2012/09/indias-drug-patent-rules, visited on 15th Feb. 2015
- Available at,http://www.economist.com/blogs/schumpeter/2012/09/indias-drug-patent-rules, visited on 15thFeb. 2015
- Mudur G., Final hearings begin in epic legal battle over Novartis drug in India. BMJ.2012;345(6257):1–2
- Inside story - India: human lives vs. Pharma profits. http://www.youtube.com/watch?v=F1U-1bjcYE8, visited on 15th Feb. 2015
- Available at, http://world.time.com/2012/08/21/howan-indian-patent-case-could-shape-the-future-of-generic-drugs/
- Available at, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884017/#B4, visited on 18th Feb. 2015
- Available at, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884017/#B11, visited on 18th Feb. 2015
- Available at, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884017/#B4, visited on 18th Feb. 2015
- Available at, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884017/#B12, visited on 18th Feb. 2015
- Lee L. Trials and TRIPS-ulations: Indian patent law and Novartis AG v. Union of India., pg. 281–290, Berkeley Technol Law J. 2008;28(298)
- Available at, http://www.doctorswithoutborders.org/publications/article.cfm?id=5769&cat=briefing-documents, visited on 25th Feb. 2015 13 Roderick P, Pollock AM. India’s patent laws under pressure. Lancet. 2012;380(9846):e2–e4. doi: 10.1016/S0140-6736(12)61513-X.
- Chandra R. ‘3(d)’ effect: the novartis-glivec case, Pg. 13–15, Eco. Political Weekly. 2011; XLVI(37)
- Ibid
- Ecks S., Global pharmaceutical markets and corporate citizenship: the case of Novartis’ anti-cancer drug glivec. BioSocieties. 2008; 3:165–181. doi: 10.1017/S1745855208006091.
- Lee L., Trials and TRIPS-ulations: Indian patent law and Novartis AG v. Union of India., pg. 281–290 Berkeley Technol Law J. 2008;28(298)
- Médecins sans Frontières. Will the Lifeline of Affordable Medicines for Poor Countries be cut? Consequences of Medicines Patenting in India (Briefing Document) Geneva, Switzerland: Médecins Sans Frontières; 2005. (Médecins Sans Frontières Campaign for Access to Essential Medicines).
- Available at, http://www.economist.com/node/21562226?zid=318&ah=ac379c09c1c3fb67e0e8fd1964d5247f, visited on 25th Feb. 2015
- Roderick P, Pollock AM. India’s patent laws under pressure. Lancet. 2012;380(9846):e2–e4. doi: 10.1016/S0140-6736(12)61513-X
- Billingsley M., Novartis challenges India’s drug patent laws in supreme court. Pg. 1, BMJ.2012;344(1279)
- Mudur G., Final hearings begin in epic legal battle over Novartis drug in India. Pg.1–2, BMJ.2012;345(6257)
- Chandra R. ‘3(d)’ effect: the novartis-glivec case. Pg.13–15, Eco. Political Weekly. 2011;XLVI(37)
- Available at, http://www.eastasiaforum.org/2013/04/26/novartis-vs-the-government-of-india-patents-and-publichealth/
- Available at, http://www.ip-watch.org/2013/04/01/novartis-loses-patent-bid-lessons-from-indias-3d-experience/, visited on 25th Feb. 2015
- Available at, http://www.pharmatimes.com/article/13-04-02/Novartis_loses_Indian_Glivec_patent_case.aspx, visited on 29th Feb. 2015
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 124
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 86